Eli Lilly on Wednesday introduced its Mounjaro KwikPen in India, pricing the starting 2.5-mg dose at 14,000 rupees (about US$160) for a month’s supply. The once-weekly injector is available in six strengths ranging from 2.5 mg to 15 mg, with the highest dose costing 27,500 rupees, the company said. The launch intensifies competition with Novo Nordisk, whose Wegovy pen retails at 17,345–26,015 rupees depending on dose. India’s drug regulator cleared the Mounjaro pen in June, two days after authorising Wegovy. Lilly began selling Mounjaro vials in March; demand for the GLP-1 therapy has driven month-on-month sales to double by July, according to company data. Mounjaro (tirzepatide) and Wegovy (semaglutide) belong to the fast-growing GLP-1 class that helps control blood sugar and promote weight loss. Lower Indian prices could broaden access in a country with more than 100 million adults living with diabetes, while providing Lilly a foothold in a market where Novo has long enjoyed an early-mover advantage.